A detailed history of J. Goldman & CO LP transactions in Uni Qure N.V. stock. As of the latest transaction made, J. Goldman & CO LP holds 67,500 shares of QURE stock, worth $2.02 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
67,500
Previous 121,600 44.49%
Holding current value
$2.02 Million
Previous $1.7 Million 132.39%
% of portfolio
0.12%
Previous 0.05%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

BUY
$10.6 - $18.08 $815,309 - $1.39 Million
76,916 Added 150.49%
128,026 $1.36 Million
Q4 2024

Feb 14, 2025

SELL
$4.54 - $17.73 $827,442 - $3.23 Million
-182,256 Reduced 78.1%
51,110 $902,000
Q3 2024

Nov 14, 2024

BUY
$3.78 - $10.12 $103,337 - $276,660
27,338 Added 13.27%
233,366 $1.15 Million
Q2 2024

Aug 14, 2024

SELL
$4.39 - $5.43 $1.34 Million - $1.65 Million
-304,477 Reduced 59.64%
206,028 $923,000
Q1 2024

May 15, 2024

BUY
$4.82 - $6.93 $2.46 Million - $3.54 Million
510,505 New
510,505 $2.65 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $1.4B
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track J. Goldman & CO LP Portfolio

Follow J. Goldman & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.